Breathing in xenon: a new MRI scan to see lung damage?
NCT ID NCT05241275
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study at Duke University tests whether a special MRI scan using inhaled xenon gas can detect changes in lung function over time in people with progressive pulmonary fibrosis. Sixty adults with various types of lung scarring will have MRI scans before starting anti-fibrotic medication and again at 3, 6, and 12 months. The goal is to see if this imaging method can measure how the lungs respond to treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Hyperpolarized 129 Xenon gas (used as an imaging agent for MRI)
- What this could lead to
- If successful, this could provide a new way to monitor lung disease progression and treatment response without invasive tests.
- What could go wrong
- This is a small, early-phase study (60 people) at one center. The imaging technique is experimental and may not prove reliable or widely usable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
60 people
The number who actually took part.
- Started
-
Jul 2022
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * We will include all patients who are over 18 years of age with a physician-diagnosed ILD of one of the below subtypes based on multidisciplinary consensus 1. Chronic hypersensitivity pneumonitis 2. Autoimmune interstitial lung disease (including rheumatoid arthritis-ILD, mixed connective tissue disorder related ILD, myositis related ILD, scleroderma related ILD, and idiopathic pneumonia with autoimmune features) 3. Idiopathic NSIP 4. Unclassifiable idiopathic interstitial pneumonia * Fibrotic lung disease affecting more than 10% of lung volume on high-resolution CT, per Duke radiology review * Evidence of any of the following criteria for progression of ILD within the 24 months before screening: 1. Relative decline in FVC % predicted of at least 10% 2. Relative decline in FVC % predicted ≥ 5% - \< 10 combined with either increasing extent of fibrotic changes on HRCT or worsening of respiratory symptoms 3. Worsening respiratory symptoms and increased extent of fibrosis on HRCT * Willing and able to give informed consent and adhere to visit/protocol schedules * Immunosuppressive medication, including azathioprine, cyclosporine, mycophenolate mofetil, rituximab, cyclophosphamide, or oral glucocorticoids are permitted at the discretion of the treating physician Exclusion Criteria: * Subject is less than 18 years of age * Prior treatment with nintedanib or pirfenidone * Subject is pregnant or lactating * Prior investigational drug use within 28 days * MRI is contraindicated based on responses to MRI screening questionnaire * Respiratory illness of a bacterial or viral etiology within 30 days of MRI * Acute exacerbation within 30 days of MRI, defined by acute increases in oxygen requirement, bilateral alveolar filling opacities on imaging, and the need for antibiotics and/or systemic steroids * Subject does not fit into 129Xe vest coil used for MRI * Subject with ventricular cardiac arrhythmia in the past 30 days. * Subject has history of cardiac arrest within the last year * Subject deemed unlikely to be able to comply with instructions during imaging * Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Autoimmune interstitial lung disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Patients and families build a living database of pulmonary fibrosis
- Can pulmonary fibrosis patients pull hard enough for their inhalers?
- Inhaled therapy aims to slow the march of progressive pulmonary fibrosis
- Can a thousand patient records unlock better care for a rare lung disease?
- Sharper CT scans may solve a lung disease diagnostic puzzle
- Can we untangle the overlap of lung diseases? a new study aims to find out